Antonia, S. J., Bendell, J., Taylor, M., Calvo, E., Jaeger, D., de Braud, F., … Eder, J. P. (2015). Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. In ANNALS OF ONCOLOGY (Vol. 26, pp. 74–75). Rome, ITALY: OXFORD UNIV PRESS.

Antonia, S. J., J. Bendell, M. Taylor, E. Calvo, D. Jaeger, F. de Braud, P. A. Ott, et al. “Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.” In ANNALS OF ONCOLOGY, 26:74–75. OXFORD UNIV PRESS, 2015.

Antonia SJ, Bendell J, Taylor M, Calvo E, Jaeger D, de Braud F, et al. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. In: ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2015. p. 74–5.

Antonia, S. J., et al. “Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.” ANNALS OF ONCOLOGY, vol. 26, OXFORD UNIV PRESS, 2015, pp. 74–75.

Antonia SJ, Bendell J, Taylor M, Calvo E, Jaeger D, de Braud F, Ott PA, Pietanza MC, Horn L, Le DT, Morse MA, Lopez-Martin JA, Ascierto PA, Christensen O, Grosso JF, Simon J, Lin C, Eder JP. Phase 1/2 study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. ANNALS OF ONCOLOGY. OXFORD UNIV PRESS; 2015. p. 74–75.